Trial Profile

A phase III study of AVP-923 for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dextromethorphan/quinidine (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use

Most Recent Events

25 Sep 2015 New trial record
22 Sep 2015 According to Avanir Pharmaceuticals media release, company is planning to start this program called TRIAD later this year

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com